| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3405359 | Journal des Anti-infectieux | 2016 | 5 Pages |
Abstract
The management of patients harboring emergent highly resistant bacteria (EHRB) has been defined by national recommendations in 2013. They do not differ from ongoing recommendations in northern European countries for multiresistant hospital bacteria, including methicillin resistant Staphylococcus aureus (MRSA). Recommended measures are effective, both against MRSA in Scandinavian countries and against EHBR in France. However, their strictness makes them sometime complex to apply. This article reviews efficacy and cost of these measures.
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
J.-C. Lucet, G. Birgand,